Pinealon

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) belonging to the group of short peptides described in the Russian literature as bioregulators. It is supplied as a lyophilised powder. Identity confirmation by mass spectrometry is unambiguous for a peptide of this size, and purity is determined by reversed-phase HPLC; for very short, highly polar peptides the chromatographic method must be appropriate to the analyte, and a purity figure quoted without its method should not be accepted. Values on this record are transcribed from supplier documentation.

The compound emerged from a Russian research programme on short peptide bioregulators, developed from the 1980s onward, which proposed that tri- and tetrapeptides derived from tissue extracts act as regulators of gene expression in the tissues from which they were derived. Pinealon was assigned to the pineal and central nervous system group within that framework. The programme's output is largely self-contained, with limited engagement from research communities outside it.

Published work examines proposed interaction of short peptides with DNA and histone-associated regions, effects on gene expression in cell culture, effects on markers of oxidative stress in neuronal culture, and behavioural and survival endpoints in rodent models of hypoxia and prenatal stress. The proposed mechanism of direct peptide-DNA interaction as a means of gene regulation is central to the programme's theoretical framework.

Little in this record qualifies. The compound is analytically simple and readily verified by mass spectrometry, and its physicochemical characterisation is not in dispute. Beyond identity and purity, there is no body of findings that meets a strong-evidence threshold, and it would be misleading to present one.

There are no randomised controlled human trials of any size. The published record is small, concentrated in a single research tradition, and largely published in journals with limited international indexing and limited independent peer review. The central mechanistic proposition — that short peptides regulate gene expression through direct interaction with DNA at physiologically relevant concentrations — has not been independently established by groups outside the originating programme, and it is not a mechanism accepted in the broader molecular biology literature. Rodent studies use small groups, and reported endpoints are frequently behavioural with limited blinding detail. Pharmacokinetic data are absent. A reader evaluating this compound should treat it as a subject of an isolated research programme rather than an established pharmacological agent, and this monograph is short because the literature is.

Store the lyophilised solid as stated on this record, protected from light and moisture, and equilibrate the sealed vial before opening. Short polar peptides are strongly hygroscopic and degrade fastest under humidity and repeated temperature cycling. This section describes laboratory handling of the material as supplied only; no preparation or administration procedure is provided.

Any indexed citations verified by PMID appear below; where claims exist only in non-indexed sources, they are not cited here, and their absence is itself informative. See testing methodology and sourcing standards.